More than 14 million people are battling cancer in the United States today. That number is said to rise to abound 19 million by the year 2024, according to the National Cancer Institute. Great strides have been made in medical and cancer research, but still there was much more to be done. After experiencing the heart breaking breast cancer that his wife was diagnosed with, Eric Lefkofsky wanted to establish a means of bringing cancer diagnosis and treatment into the twenty first century. Eric co-founded Tempus, which is a company that has made many advances and has taken the lead in data of precision medicine that is data enabled. The health care industry was lagging behind in modern technology, and had not developed the use of electronic health records. Doctors were still using hand written notes that were not always easily accessible. He found that data collection and digital technology were not effectively combined. The goal of Tempus was to make a transformation in the way that cancer care was delivered. It developed a platform that analyzed the molecular as well as the clinical data of the cancer patient.
Eric Lefkofsky, a co-founder of Tempus, is also the Chief Executive Officer. He is an entrepreneur and a philanthropist. In 2006, he and his family established the Lefkofsky Family Foundation, a private charitable organization who’s mission is to help enhance the quality of human life. He is a graduate of The University of Michigan, and received his Juris Doctorate from The University of Michigan Law School. Eric is also the published author of the book, Accelerated Disruption. With the co founding of the technology company Tempus, the world’s largest library of molecular and clinical data. doctors can now deliver a more personalized treatment and care for their cancer patients. Now patients can benefit from the treatment that has been done for others through a data base of pertinent clinical and molecular information.
Eric Lefkofsky info: www.tempus.com/about-us/
As important as cancer treatment is, there are still plenty of issues that impede its progress and prevent medical facilities from being able to help people as efficiently as they otherwise could. Eric Lefkofsky understands this problem, and that’s why he’s gone to great lengths to develop Tempus, a startup that specializes in improving access to medical data.
Through Tempus, research that should otherwise flow freely is able to do exactly that. Whereas data from various research facilities typically kept close to the chest, Tempus helps bring all of it together and make it readily accessible. This not only helps research facilities get more information, but it also helps to ensure that patients are treated appropriately given their specific needs. As Eric Lefkofsky himself puts it, research facilities often struggle to keep track of the specific treatments that each patient is undergoing, in addition to any related to their cancer therapy. If it’s difficult for a researcher to keep track of any extenuating circumstances, then that also hampers any ongoing research in the long run. By eliminating this possibility, Tempus can ensure that facilities get exactly the information they need, whenever they need it.
For his part, Lefkofsky is no stranger to helping people come together for a greater good. After previously founding Groupon, Eric Lefkofsky decided to set up his next venture when his wife developed breast cancer. Realizing that cancer treatment was lagging behind compared to other fields, and that the potential solution was relatively simple, Lefkofsky decided to build a company that could provide alternative access to the data that facilities need on a daily basis.
Now, Lefkofsky has built a technological layer that helps to integrate existing medical and pathology systems into a single cohesive unit. By aggregating all of this data, Lefkofsky hopes to not only help his wife, but cancer patients around the world as well. Of course, the potential for Tempus extends beyond cancer research. Lefkofsky foresees a future where neuroscientists use his system, as well as doctors who are developing personalized vaccines for individual patients. The idea is that this system will only help to improve medical systems around the world and improve their performance for the betterment of everyone. And, as it stands, it appears to be doing exactly that.
To know more visit @: www.insidephilanthropy.com/guide-to-individual-donors/eric-lefkofsky.html